Founded in 2017, JURA Bio has developed an end-to-end generative machine learning and synthetic biology platform for the discovery and development of genetic medicines. With a focus on developing drugs built around the TCR-epitope-HLA synapse, they are developing a best-in-class map from any antigen-HLA pair to any T cell receptor; such a map would broadly advance the development of therapeutics for oncology and autoimmune dis...
Founded in 2017, JURA Bio has developed an end-to-end generative machine learning and synthetic biology platform for the discovery and development of genetic medicines. With a focus on developing drugs built around the TCR-epitope-HLA synapse, they are developing a best-in-class map from any antigen-HLA pair to any T cell receptor; such a map would broadly advance the development of therapeutics for oncology and autoimmune disease. JURA Bio is based in Boston, MA.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.